https://www.selleckchem.com/products/hg6-64-1.html ssociated with epithelial-mesenchymal transition conversion. These preoperative radiological results will help to predict epithelial-mesenchymal transition conversion in lung adenocarcinoma. The primary objective was to identify well-tolerated doses of cimlanod in patients with acute heart failure (AHF). Secondary objectives were to identify signals of efficacy, including biomarkers, symptoms, and clinical events. Nitroxyl (HNO) donors have vasodilator, inotropic and lusitropic effects. Bristol-Myers Squibb-986231 (cimlanod) is an HNO donor being developed for acute heart failure (AHF). This was a phase IIb, double-blind, randomized, placebo-controlled trial of 48-h treatment with cimlanod compared with placebo in patients with left ventricular ejection fraction≤40% hospitalized for AHF. In part I, patients were randomized in a 11 ratio to escalating doses of cimlanod or matching placebo. In part II, patients were randomized in a 111 ratio to either of the 2 highest tolerated doses of cimlanod from part I or placebo. The primary endpoint was the rate of clinically relevant hypotension (systolic blood pressure<90mmHg or patients became symptomatic). In part I (n=100), clinically relevanot persist beyond the treatment period. (Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure [STANDUP AHF]; NCT03016325). This study sought to compare the performance of a novel drug-coated balloon (DCB) (Elutax SV, Aachen Resonance, Germany), with an everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, California) in patients with de novo lesions. Small vessel coronary artery disease (SVD) represents one of the most attractive fields of application for DCB. To date, several devices have been compared with drug-eluting stents in this setting, with different outcomes. The PICCOLETO II (Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment)